Precigen, Inc. ((PGEN)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Precigen, Inc. is conducting a Phase 2 clinical study titled ‘A Randomized, Open-label, Two-arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy in Patients With Recurrent or Metastatic Cervical Cancer.’ The study aims to assess the efficacy and safety of combining PRGN-2009 with pembrolizumab compared to pembrolizumab alone in patients with recurrent or metastatic cervical cancer resistant to pembrolizumab. This research is significant as it explores potential new treatment avenues for a challenging cancer type.
The study tests two interventions: PRGN-2009 combined with pembrolizumab, and pembrolizumab alone. PRGN-2009 is a biological treatment administered subcutaneously, while pembrolizumab is a drug given intravenously. The combination aims to enhance treatment efficacy in resistant cervical cancer cases.
This interventional study is randomized with a parallel assignment model and is open-label, meaning both researchers and participants know which treatment is being administered. The primary purpose is treatment-focused, seeking to improve outcomes for patients with limited options.
The study began on November 27, 2023, and the primary completion date is yet to be announced. The last update was submitted on August 27, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
For investors, this study could influence Precigen’s stock performance positively if successful, as it may lead to a new effective treatment for cervical cancer. The involvement of the National Cancer Institute as a collaborator underscores the study’s importance. Competitors in the oncology sector will be watching closely, as advancements here could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.